Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 3, 2026International Journal of Medical Robotics and Computer Assisted Surgery

Signal Detection and Temporal Analysis of Aromatase Inhibitor‐Associated Hepatotoxicity: A Pharmacovigilance Study Integrating Bayesian Belief‐Propagation Network and Frequentist Metrics

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYu-Ke LiHZHongmei ZhengYWYanting Wang

Discussion

Loading...

Member takes

Overview

Pharmacovigilance study assesses hepatotoxicity of aromatase inhibitors, highlighting the need for proactive monitoring.

Key Points

  • Assess real-world hepatotoxicity associated with third-generation aromatase inhibitors for breast cancer.
  • Analyzed FAERS data from Q1 2004 to Q1 2025 using disproportionality analysis framework.
  • Incorporated traditional frequentist metrics and Bayesian belief-propagation network.
  • Identified 24 liver-related adverse events and 7 clinical outcomes.
  • Letrozole had the highest number of hepatotoxicity cases and signal support.
  • Exemestane showed the earliest hepatotoxicity onset at a median of 49 days, significantly earlier than anastrozole and letrozole.

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a70402275942ff7265e4dc1https://doi.org/10.1002/rcs.70216
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adverse Event Profiles of the Third-Generation Aromatase Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS2024 · 7 citations
  2. 2Association study of aromatase inhibitors and adverse events related to osteoporosis: based on pharmacovigilance data2026 · 3 citations
  3. 3Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment2024 · 13 citations
  4. 4Comparative risk of osteopenia, osteoporosis, and pathological fractures in breast cancer patients treated with steroidal versus non-steroidal aromatase inhibitors: A large-scale real-world data analysis.2026
  5. 5Disproportionality analysis of musculoskeletal and connective tissue disorders associated with aromatase inhibitors: A real-world pharmacovigilance study.2026